论文信息 - 973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC - 字舞流文

973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC

P. Schwarzenberger | J. Gray | M. Reck | N. Peled | S. Powell | F. Grossi | R. Jennens | R. Hui | E. Garon | T. Kurata | H. Bischoff | E. Felip | D. Rodríguez Abreu | S. Gadgeel | M. Dómine Gómez | M. Hochmair | M. Garassino | E. Jensen | G. Speranza | E. Esteban González